Grace Therapeutics Files 8-K

Ticker: GRCE · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1444192

Grace Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyGrace Therapeutics, INC. (GRCE)
Form Type8-K
Filed DateJun 25, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, name-change

TL;DR

Grace Therapeutics (fka Acasti Pharma) filed an 8-K on 6/25/25. Nothing major disclosed yet.

AI Summary

Grace Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on other events and financial statements. The company, formerly known as Acasti Pharma Inc. until August 28, 2008, is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This filing indicates ongoing corporate activity and reporting requirements for Grace Therapeutics, Inc., formerly Acasti Pharma Inc.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' without specific material disclosures of new risks.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported in this 8-K filing?

The filing indicates 'Other Events' as an item, but the specific details of these events are not provided in the excerpt.

When did Grace Therapeutics, Inc. change its name from Acasti Pharma Inc.?

The company's name was changed from Acasti Pharma Inc. on August 28, 2008.

Where are Grace Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.

What is the SIC code for Grace Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Grace Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the fiscal year end for Grace Therapeutics, Inc.?

The fiscal year end for Grace Therapeutics, Inc. is March 31 (0331).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding Grace Therapeutics, Inc. (GRCE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing